Mohamed Asfour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamed Asfour has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Huseyin Bozbas
Department of Cardiology, TOBB University of Economics and Technology, Faculty of Medicine, Ankara, Türkiye
4 shared publications - Savas Celebi
Department of Cardiology, TOBB Economics and Technology University Medical School, Ankara, Turkey
2 shared publications - Basri Amasyali
TOBB Ekonomi ve Teknoloji Universitesi - Cardiology, Ankara - Turkey
1 shared publication - Bengisu Şahin
Department of Cardiology, TOBB University of Economics and Technology Faculty of Medicine , Ankara
1 shared publication - Burak Emre Onuk
Cardiovascular Surgery Department, TOBB ETU Hospital, Ankara, Turkey
1 shared publication - Cem Barçın
Department of Cardiology, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Türkiye
1 shared publication
Latest Publications
- Open Access
- 30 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (10)
Resolution of Lancisi’s sign following bicaval TricValve implantation for torrential tricuspid regurgitation: a case report defining a novel bedside marker of haemodynamic recovery
Background: Caval valve implantation (CAVI) using the TricValve system is an emerging treatment option for severe tricuspid regurgitation (TR) in patients who are unsuitable for surgery or orthotopic transcatheter intervention. Lancisi's sign is a classical manifestation of severe TR; however, its resolution after CAVI has not been described. Case summary: An 85-year-old woman with recurrent right heart failure and torrential TR presented with prominent bilateral Lancisi's sign. Echocardiography revealed severe annular dilatation (48 mm), right ventricular dysfunction (TAPSE, 13 mm), and a left ventricular ejection fraction of 40%. Owing to prohibitive surgical risk (EuroSCORE II 18.4%; TRI SCORE 14), she underwent successful implantation of 29-mm superior vena cava and 35-mm inferior vena cava TricValve prostheses. At 3 months, Lancisi's sign had completely resolved, NYHA functional class improved from III-IV to I-II, NT-proBNP decreased from 25 000 to 2 000 pg/mL, TAPSE increased from 13 to 20 mm, and no rehospitalization or device-related adverse event occurred. We report a structured single-patient case using clinical examination, echocardiography, invasive hemodynamic assessment, laboratory markers, and 3-month follow-up after bicaval TricValve implantation. Discussion: Bicaval TricValve implantation resulted in marked symptomatic, biochemical, echocardiographic, and bedside clinical improvements. The resolution of Lancisi's sign may represent a simple marker of hemodynamic recovery after CAVI.
- 30 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (10)
Open AccessResolution of Lancisi’s sign following bicaval TricValve implantation for torrential tricuspid regurgitation: a case report defining a novel bedside marker of haemodynamic recovery
Background: Caval valve implantation (CAVI) using the TricValve system is an emerging treatment option for severe tricuspid regurgitation (TR) in patients who are unsuitable for surgery or orthotopic transcatheter intervention. Lancisi's sign is a classical manifestation of severe TR; however, its resolution after CAVI has not been described. Case summary: An 85-year-old woman with recurrent right heart failure and torrential TR presented with prominent bilateral Lancisi's sign. Echocardiography revealed severe annular dilatation (48 mm), right ventricular dysfunction (TAPSE, 13 mm), and a left ventricular ejection fraction of 40%. Owing to prohibitive surgical risk (EuroSCORE II 18.4%; TRI SCORE 14), she underwent successful implantation of 29-mm superior vena cava and 35-mm inferior vena cava TricValve prostheses. At 3 months, Lancisi's sign had completely resolved, NYHA functional class improved from III-IV to I-II, NT-proBNP decreased from 25 000 to 2 000 pg/mL, TAPSE increased from 13 to 20 mm, and no rehospitalization or device-related adverse event occurred. We report a structured single-patient case using clinical examination, echocardiography, invasive hemodynamic assessment, laboratory markers, and 3-month follow-up after bicaval TricValve implantation. Discussion: Bicaval TricValve implantation resulted in marked symptomatic, biochemical, echocardiographic, and bedside clinical improvements. The resolution of Lancisi's sign may represent a simple marker of hemodynamic recovery after CAVI.
- Open Access
- 1 January 2025
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 29 (5) , 261-264
Caval Valve Implantation Procedure in 7 Cases of Torrential Tricuspid Regurgitation and Step-by-Step Description of the Procedure
- 1 January 2025
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 29 (5) , 261-264
Open AccessCaval Valve Implantation Procedure in 7 Cases of Torrential Tricuspid Regurgitation and Step-by-Step Description of the Procedure
- 1 September 2023
- Published by Turkiye Kalp Ve Saglik Vakfi Iktisadi Isletmesi in e-Journal of Cardiovascular Medicine
- Vol. 11 (3) , 123-126
Successful Balloon Valvuloplasty in a Patient with Severe Bioprosthetic Tricuspid Valve Stenosis: Case Report
- 1 September 2023
- Published by Turkiye Kalp Ve Saglik Vakfi Iktisadi Isletmesi in e-Journal of Cardiovascular Medicine
- Vol. 11 (3) , 123-126
Successful Balloon Valvuloplasty in a Patient with Severe Bioprosthetic Tricuspid Valve Stenosis: Case Report